Abstract
Because of increasing resistance of malaria parasites to artemisinin and partner drugs, especially in Southeast Asia, new antimalarials are needed. In a multicenter, open-label, phase 2, manufacturer-sponsored trial, investigators in Thailand and Vietnam assessed the antimalarial efficacy, safety, and pharmacokinetic profile of KAF156 (an imidazolopiperazine). This agent has activity against blood stages and the preerythrocytic liver parasite stages. They enrolled adults with uncomplicated Plasmodium vivax or Plasmodium falciparum malaria . Cohorts 1 and …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
